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Abstract 
Objective: To evaluate the role of wireless capsule endoscopy in identifying small bowel 
lesions in pediatric patients with newly diagnosed colonic inflammatory bowel disease 
(IBD) type unclassified (IBDU), and to assess whether capsule endoscopy findings result 
in altered patient management. 
Methods: Ten pediatric patients recently diagnosed with IBDU through standard 
investigations were recruited from the pediatric gastroenterology clinic at McMaster 
Children’s Hospital to undergo capsule endoscopy using the Pillcam SBTM (Given Imaging) 
capsule. Findings consistent with a diagnosis of Crohn’s disease required the identification 
of at least three ulcerations. 
Results: Three out of ten patients had newly identified findings on capsule endoscopy 
that met criteria for Crohn’s disease. Three more patients had findings suspicious for 
Crohn’s disease, but failed to meet the diagnostic criteria. Three additional patients 
had findings most consistent with ulcerative colitis, and one had possible gastritis with 
a normal intestine. Findings from capsule endoscopy allowed for changes in the medical 
management of three patients. In all ten cases, capsule endoscopy allowed for a better 
characterization of the type and extent of disease. No adverse outcomes occurred in 
the present cohort. 
Conclusion: This prospective study reveals that wireless capsule endoscopy is feasible, 
valuable, and non-invasive, offering the ability to potentially better characterize newly 
diagnosed pediatric IBDU cases by identifying lesions in the small bowel and reclassifying 
these as Crohn’s disease. 
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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PALAVRAS-CHAVE
Cápsula endoscópica;
Doença inflamatória 
intestinal 
inespecífica;
Pediátrico
Papel da cápsula endoscópica na reclassificação da doença inflamatória intestinal em 
crianças
Resumo 
Objetivo: Avaliar o papel da cápsula endoscópica na identificação de lesões no intestino 
delgado em pacientes pediátricos com DII inespecífica (DIII) diagnosticada recentemente 
e avaliar se os achados da cápsula endoscópica resultam em alterações no tratamento 
dos pacientes. 
Métodos: Dez pacientes pediátricos recém-diagnosticados com DIII por meio de investi-
gações padrão foram recrutados da clínica de gastroenterologia pediátrica no McMaster 
Children’s Hospital, para serem submetidos a exame com a cápsula endoscópica Pillcam 
SBTM (Given Imaging). Achados compatíveis com o diagnóstico da doença de Crohn exigi-
ram a identificação de pelo menos três ulcerações. 
Resultados: De 10 pacientes, três apresentaram achados novos com a cápsula endoscópi-
ca que satisfizeram o critério para a doença de Crohn. Outros três apresentaram achados 
com suspeita de doença de Crohn, porém não atenderam nossos critérios de diagnóstico. 
Apresentaram achados mais compatíveis com colite ulcerativa outros três pacientes, e 
um apresentava possível gastrite com intestino normal. Os achados da cápsula endoscó-
pica possibilitaram mudanças no tratamento médico de três pacientes. Em todos os dez 
casos, a cápsula endoscópica permitiu uma melhor caracterização do tipo e da extensão 
da doença. Não houve resultado adverso em nossa coorte. 
Conclusão: Este estudo prospectivo revela que a cápsula endoscópica é viável, útil e não 
invasiva, que oferece a possibilidade de melhor caracterização de casos de DIII pediá-
tricos recém-diagnosticados ao identificar lesões no intestino delgado e reclassificá-las 
como doença de Crohn. 
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.  
Introduction
Inflammatory bowel disease (IBD) is increasing in prevalence 
among children. Using current standard investigations, 
between 5% and 20% of newly identified cases of IBD 
with pure colonic involvement cannot be definitively 
categorized as Crohn’s disease (CD) or as ulcerative colitis 
(UC).1,2 This translates to an incidence of 1.6-2.4/100,000 
of “indeterminate” IBD, otherwise known as colonic IBD 
type unclassified (IBDU).1 A diagnosis of indeterminate 
colitis is based on clinical and endoscopic features, along 
with indeterminate histologic samples revealing areas of 
minimal to moderate glandular distortion alternating with 
areas of regular epithelium, and presence of inflammatory 
cells in the basal part of the lamina propria.1,3,4 Some 
authors suggest that the term “indeterminate colitis” 
should be reserved for patients with surgical specimens, 
while the IBDU should be used for patients without surgical 
specimen.1 Regardless of the term used, without a clear 
diagnosis, management of these patients is obscure, based 
on clinical suspicion, and modified by trial and error. 
Establishing the specific disease process early on is likely to 
present clinical benefits by allowing for earlier institution 
of appropriate management. 
Wireless capsule endoscopy (WCE) is a novel tool that 
provides detailed color images of the gastrointestinal tract. 
The wireless capsule offers non-invasive visualization of 
large spans of the small intestine that are otherwise not 
entirely accessible by upper and lower endoscopy. The 
capsule, measuring 11 mm x 26 mm, transmits images at 
a rate of two frames per second, and has a battery life 
of six to eight hours.5 In adults, capsule endoscopy has 
been found to be clinically useful in managing confirmed 
or suspected cases of IBD. The diagnostic yield of WCE in 
confirming suspected CD in adults ranges between 38% 
and 75%, depending on the study and the criteria used to 
suggest underlying CD.6 While WCE is potentially useful to 
categorize IBDU patients, a negative WCE does not exclude 
a future diagnosis of CD.1 
At present, capsule endoscopy has been used in a 
limited fashion in pediatric patients. The goal of this pilot 
study is to investigate the role of WCE in identifying small 
bowel lesions not otherwise identified by current standard 
investigations in pediatric patients with newly diagnosed 
IBDU. 
Methods
This was a prospective study to recruit patients from the 
McMaster Children’s Hospital pediatric gastrointestinal 
clinic who were diagnosed with IBDU via standard 
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evaluation between the years of 2008 and 2009. Routine 
investigations included: complete blood count, erythrocyte 
sedimentation rate, C-reactive protein, albumin, ferritin, 
anti-Saccharomyces cerevisae antibodies, p-anti-neutrophil 
cytoplasmic antibody, small bowel follow through (SBFT), 
as well as upper and lower endoscopies. Inclusion criteria 
were patients with IBDU, between 5 and 17 years of 
age, who had a normal SBFT prior to capsule endoscopy. 
Exclusion criteria were previously established diagnoses of 
CD or UC, with an abnormal SBFT. Being a novel pilot study, 
the current standard of investigation and of care was used 
for comparison. The Ethics Review Board of the McMaster 
Children’s Hospital approved the study; an informed consent 
was obtained from all patients.
In the pediatric gastrointestinal laboratory, nine patients 
swallowed a Pillcam SBTM (Given Imaging) capsule following 
a 12-hour fast. A single patient was unable to swallow the 
capsule secondary to anxiety, so endoscopic insertion with 
a Roth Net was employed in this case. In all cases, no bowel 
preparation was used. Once the capsule was ingested, 
patients were instructed not to drink for the first two hours, 
and not to eat for the first four hours after the beginning 
of the study. WCE images were later downloaded to the 
workstation. Two weeks after completion of the study, an 
abdominal radiograph was performed if the capsule had 
not been observed to have been eliminated in the stool. 
All patients were followed regularly in the routine IBD 
clinic. The duration of study involved a six-month period 
of enrolment, and a follow-up of 12 months for each 
patient. Study images were reviewed by an experienced 
gastroenterologist (AS). Adequacy of capsule endoscopy 
required good quality images capturing the terminal ileum 
or cecum. Since criteria for the diagnosis of CD via WCE has 
not been established or validated to date, stringent criteria 
adopted from the adult literature were implemented. Three 
or more ulcerations in the small intestine visualized by WCE 
were required in order to be consistent with a diagnosis 
of CD.7 Ulcers were characterized by lesions within a 
crater with surrounding erythema, whereas erosions were 
described as superficial white lesions with surrounding 
erythema.7 Isolated erosions, villous atrophy, and mucosal 
breaks were not considered evidence of CD. 
The primary outcome was to determine whether capsule 
endoscopy would identify new small bowel lesions in patients 
with IBDU that were not recognised via conventional studies, 
and to assess whether these newly identified lesions fulfil 
the criteria adopted to suggest CD. As a secondary outcome, 
it was evaluated whether findings from WCE allowed for 
changes in medical management. Descriptive statistics 
including range, frequencies, proportions, and medians 
were used to describe the study population. All adverse 
events were recorded. 
Results
Ten patients with the diagnosis of IBDU who met the inclusion 
criteria were consecutively recruited. Their demographic 
and clinical characteristics are listed in Table 1, as well 
as the findings from the standard investigations. In all ten 
cases, images were of great quality and image adequacy 
was met. In fact, for all cases, images provided a better 
characterization of the location and extent of disease. 
There were no cases of retained or impacted capsules, 
and no abdominal radiographs were required. No adverse 
events occurred in the present cohort. 
WCE allowed for the identification of lesions meeting the 
adopted criteria suggestive of CD in three of ten patients. 
Three additional patients had findings suspicious for CD, 
but failed to meet the outlined criteria. Three others had 
large intestine pathology most consistent with UC. The 
last patient had a normal appearing intestine; however, 
WCE images were suggestive of esophagitis, and he was 
later confirmed to have a fungal esophagitis, when upper 
endoscopy was repeated.
Modifications in patient management attributable to 
data gained by WCE included both intensification and 
de-escalation of treatment. Overall, three patients had a 
change in medical management in light of findings obtained 
by WCE. 
Discussion
WCE is a valuable tool that offers a non-invasive means 
of obtaining high quality images of the mucosal lining of 
the gastrointestinal tract, including segments that are not 
accessible with conventional methods. WCE is particularly 
convenient and advantageous in the pediatric population, 
as it does not require bowel preparation, radiation, general 
anaesthesia, or IV deep sedation.8 Sant’Anna et al. were 
the first to explore the use of WCE in identifying obscure 
disorders of the small intestine in pediatric patients.9,10 Since 
then, the application of WCE in pediatric gastroenterology 
has grown to include numerous roles, including the 
investigation of IBD.8,11-15 The North American Society for 
Pediatric Gastroenterology, Hepatology, and Nutrition has 
concluded that WCE has a role in the identification of CD in 
the small intestine.11 Though capsule impaction is a major 
risk of WCE, occurring in approximately 3.5% of pediatric 
patients,16 the United States Food and Drug Administration 
(FDA) has approved the use of WCE in children over the age 
of 2 years.17,18 Others report that WCE is feasible and safe 
in children as young as 1.5 years old.12 
The major predicament of WCE is the inability to 
concurrently sample tissue for histologic confirmation of 
disease.5,14,19-21 Although integration of tissue sampling in WCE 
is underway,22 gastroenterologists are currently left without a 
gold standard to assess the accuracy, sensitivity, or specificity 
of WCE findings.23 Non-steroidal anti-inflammatory drugs 
(NSAID) usage has been associated with a high prevalence of 
bowel injury, necessitating the discernment of these lesions 
from those of underlying IBD.24 More troublesome is that 
mucosal breaks have been identified in the small intestine of 
15% of normal subjects, in absence of NSAID use.1,25 Without 
histological confirmation of the etiology of suspicious lesions 
visualized through WCE, it is impossible to determine with 
certainty which are evidence of CD.24 Moy et al. found that 
WCE findings of ulcerations or strictures are highly suggestive 
of CD and respond to therapy, while erosions alone are not 
sufficient to diagnose CD, and should not be used to guide 
medical therapy. 
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The present study faces the collective limitation of 
having no gold standard upon which to compare WCE 
findings, precluding definitive determination of CD. Given 
such currently inescapable limitations, the most stringent 
criteria adopted from adult studies were implemented, 
while abiding by Moy et al.’s findings so as to limit false 
positive cases of CD identified by WCE. WCE was unique 
in identifying convincing evidence to reclassify three of 
ten patients as having lesions consistent with CD, where 
standard investigations failed to identify such lesions. WCE 
also provided objective findings instigating the appropriate 
modifications in the medical management of three patients. 
Additionally, there were no cases of capsule retention in 
the present cohort, and good quality WCE images were 
obtained in every case. Though a limiting factor, a small 
sample size is acceptable for the purpose of the present 
feasibility study. One point worth mentioning is that the 
study sample a highly select population of IBDU, which limits 
the assessment of the WCE utility. The best way to assess 
the diagnostic utility of the WCE would be by including 
an unselected population of IBD undergoing the diagnostic 
tests, and comparing WCE with the standard investigations 
to formally assign the IBD diagnosis. However, due to the 
cost of this test, it is more appropriate to reserve it for 
those with IBDU diagnosis.
Several retrospective studies addressed the use of WCE in 
identifying small intestine lesions among pediatric patients. 
Oloughlin et al. retrospectively studied the utility of WCE 
in detecting small intestinal lesions suggestive of CD in 24 
children, where eight cases met criteria for CD.26 Moy and 
Levine performed a larger retrospective review of 46 WCE 
in children for various indications, including unresponsive 
CD and UC.27 In their study, WCE revealed nine new cases 
of CD.27 They also compared the diagnostic yield of WCE 
and small bowel series (SBS) in children being evaluated 
for small bowel disease, and concluded that WCE revealed 
100% of the pathology identified by SBS, whereas SBS only 
recognized 47% of those identified by WCE.27 This group 
later studied the use of WCE in children with unexplained 
growth failure, in whom Celiac disease and Crohn’s disease 
were excluded via standard tests.28 Four of the seven 
patients investigated had small intestine lesions consistent 
with CD, and upon initiation of therapy, all gained weight 
and experienced symptomatic improvement.28 Similarly, 
De’Angelis et al. retrospectively investigated the diagnostic 
value of WCE in ten Italian children with suspected CD that 
could not be confirmed by endoscopy, where WCE showed 
active lesions suggesting CD in five cases.17 Cohen et al. 
retrospectively evaluated the use of WCE in 28 children with 
established CD, UC, or IBDU experiencing exacerbation or 
growth failure.29 Here, WCE identified small bowel lesions 
resulting in the reclassification of four of the five patients 
previously diagnosed with UC, and one of the two patients 
with IBDU was reclassified as having CD.29 These studies 
highlight the potential diagnostic value of WCE, along with 
its prospect in allowing changes in medical management 
and offering clinical improvements by identifying lesions 
consistent with CD not otherwise documentable.28
Although suggesting a role in identifying WCE as a novel tool 
in better categorizing patients with IBDU, the retrospective 
nature of the above studies limits their validity. To date, very 
few prospective studies have been performed in pediatric 
patients using WCE in the investigation of IBDU. Thomson 
et al. assessed the diagnostic yield of WCE in 28 children 
Table 1 Demographic and clinical characteristics and findings from the standard investigations for the study patients.
Patients (n = 10) Results
Age (years); median (range) 14.7 (9.8-17.8)
Gender; male: female 7:3
Weight (kg); median (range) 48.9 (27.5-68.1)
Height (m); median (range) 1.61 (1.34-1.73)
Body mass index (kg/m2); median (range) 19.3 (14-22.6)
EGD; n (%) 
Normal 7 (70%)
Mild gastritis 1 (10%)
Duodenal nodularity  1 (10%)
Mild esophagitis 1 (10%)
Colonoscopy; n (%) 
Microscopic colitis (normal macroscopy) 2 (20%)
Superficial continuous ulceration of the right colon 3 (30%)
Superficial continuous ulceration of transverse and left colon 3 (30%)
Multiple tiny aphthous ulcers of the recto sigmoid 2 (20%)
SBFT; n (%) 
Negative 10 (100%)
p-ANCA; n (%) 
Negative 10 (100%)
ASCA; n (%) 
Negative 10 (100%)
ASCA, antisaccharomyces cerevisae antibodies; EGD, esophagoduedenoscopy; p-ANCA, p-anti-neutrophil cytoplasmic antibody; SBFT, 
small bowel follow through.
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with various types of small bowel disease.8 In their cohort, 
16patients were known to have CD, and WCE revealed a 
greater extent of small bowel lesions consistent with CD 
than did a barium meal follow through.8 However, this group 
did not assess the evaluation of IBDU with WCE. Fritscher-
Ravens et al. performed a large prospective European 
multicenter study a looking at numerous gastrointestinal 
diseases among 83 children between 5 and 8 years of age.12 
Within this study, 20 had suspected CD that could not be 
confirmed using standard investigations.12 In this study, 
WCE identified diffuse aphthous ulceration, fissuring, and 
terminal ileitis in 11 of these 20 patients.12 Arguelles-Arias 
et al. prospectively studied the use of WCE in 12 pediatric 
patients over 12 years old with a suspicion of CD that could 
not be otherwise confirmed.23 They applied a broad range 
of diagnostic manifestations, including aphthae, mucosal 
fissures, erosions, and linear or irregular ulcers, and 
concluded that WCE identified CD in seven of 12 patients.23 
The present study differs from this one in two respects, 
which likely explains the divergent proportion of patients 
identified as having CD by WCE (seven of 12 patients in 
their study versus three of ten in the present study).23 In 
the present study more stringent criteria were applied to 
establish a high suspicion of CD, and a more comprehensive 
age group was analyzed, including a higher proportion of 
younger patients, who are less likely to have underlying IBD, 
. More recently, Gralnek et al. identified lesions suggestive 
of CD in two out of three patients with indeterminate colitis, 
using criteria similar to that of the present study, providing 
corroborative evidence that WCE is useful in identifying 
lesions not otherwise identified endoscopically.30
Unlike studies performed to date including adult 
studies, retrospective pediatric studies, or pediatric 
studies addressing a variety of gastrointestinal diseases 
at once, the present study prospectively and specifically 
addressed pediatric patients with IBDU who could not be 
better classified using standard investigations. By explicitly 
addressing this issue, it can be concluded that there is 
strong potential for the clinical utility of WCE in better 
characterizing IBDU. Though not tested in this study, it is 
anticipated that such earlier identification will translate 
into improved patient management and outcome. These 
findings emphasize the need for continued investigation, 
with large prospective randomized control trials with 
longer follow up periods to further assess the role of 
WCE in reclassifying puzzling cases of IBDU, as well as to 
assess changes in medical management and anticipated 
improvements in disease progression. 
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